Results 171 to 180 of about 3,855 (201)
Some of the next articles are maybe not open access.
Miglustat. Oxford GlycoSciences/Actelion.
Current opinion in investigational drugs (London, England : 2000), 2003Oxford GlycoSciences and Actelion have developed and launched miglustat (OGT-918; Vevesca; Zavesca) for the treatment of type 1 Gaucher disease. Miglustat is an orally administered small-molecule glucosylceramide glucosyltransferase inhibitor licensed from Searle, and it is also in development for the treatment of other glycolipid storage disorders ...
openaire +1 more source
Cipaglucosidase Alfa (Pombiliti) With Miglustat (Opfolda)
Canadian Journal of Health TechnologiesCanada’s Drug Agency (CDA-AMC) recommends that Pombiliti with Opfolda be reimbursed by public drug plans for the treatment of adult patients with late-onset Pompe disease (LOPD) weighing at least 40 kg if certain conditions are met. Pombiliti with Opfolda should only be covered to treat patients who have a confirmed diagnosis of LOPD, are able to ...
openaire +1 more source
Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study
Lancet Neurology, The, 2007Marc C Patterson, Larry Abel
exaly
Miglustat: A Review of Its Use in Niemann-Pick Disease Type C
Drugs, 2013Katherine A Lyseng-Williamson
exaly
Summary of opinion: Miglustat Dipharma,miglustat
Case Medical Research, 2018openaire +2 more sources